Inventor
GHARAT LAXMIKANT A
IN14 patents
⚠️ This page may combine multiple inventors who share the name “GHARAT LAXMIKANT A”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
GLENMARK PHARMACEUTICALS SA
12 patentsUS9439890B2Sep 13, 2016
Triazolone compounds as mPGES-1 inhibitors
GLENMARK PHARMACEUTICALS SA4 citations82
US10821100B2Nov 3, 2020
Triazolone compounds as mPGES-1 inhibitors
GLENMARK PHARMACEUTICALS SA1 citations71
US10391083B2Aug 27, 2019
Triazolone compounds as MPGES-1 inhibitors
GLENMARK PHARMACEUTICALS SA1 citations71
US9949955B2Apr 24, 2018
Triazolone compounds as mPGES-1 inhibitors
GLENMARK PHARMACEUTICALS SA2 citations71
US10988467B2Apr 27, 2021
Compounds as ROR gamma modulators
GLENMARK PHARMACEUTICALS SA0 citations57
US10344024B2Jul 9, 2019
Compounds as ROR gamma modulators
GLENMARK PHARMACEUTICALS SA0 citations47
US9975887B2May 22, 2018
Compounds as ROR gamma modulators
GLENMARK PHARMACEUTICALS SA0 citations47
US10336688B2Jul 2, 2019
Carbocyclic compounds as ROR gamma modulators
GLENMARK PHARMACEUTICALS SA0 citations46
US10189775B2Jan 29, 2019
Carbocyclic compounds as ROR gamma modulators
GLENMARK PHARMACEUTICALS SA0 citations46
US7563900B2Jul 21, 2009
Process for the preparation N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methane sulfonamido-dibenzo[b,d]furan-1-carboxamide
GLENMARK PHARMACEUTICALS SA0 citations45
US10457649B2Oct 29, 2019
Polymorphs of a mPGES-1 inhibiting triazolone compound
GLENMARK PHARMACEUTICALS SA0 citations42
US10112914B2Oct 30, 2018
Polymorphs of a mPGES-1 inhibiting triazolone compound
GLENMARK PHARMACEUTICALS SA0 citations42